Ibuprofen is under clinical development by PLx Pharma Winddown and currently in Phase II for Inflammation. According to GlobalData, Phase II drugs for Inflammation have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ibuprofen’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ibuprofen overview

PL-1100/PL-1200 (ibuprofen and phosphatidylcholine) is under development for the treatment of pain and inflammation. The drug candidate is administered orally as capsule. It is a molecular complex of ibuprofen and phosphatidylcholine. Phosphatidylcholine (PC) is a natural gastroprotective agent. It reduces the serious and common gastrointestinal side-effects caused by virtually all nonsteroidal anti-inflammatory drugs (NSAIDs). Ibuprofen is a phenylpropionic acid nonsteroidal anti-inflammatory agent. The drug candidate is based on the PlxGuard technology.

PLx Pharma Winddown overview

PLx Pharma Winddown (PLx Pharma), formerly PLx Pharma, is a pharmaceutical company. It develops patent-protected delivery systems. The company offers products such as PLxGuard delivery system, PLxGuard pipeline products, and PL1100 and PL1200 ibuprofen products. Its PLxGuard delivery system is used in the enhancement of efficacy of drugs, GI safety development, new or extended patent protection, and new drug application solutions. PLx Pharma’s lead product candidate includes Vazalore 325 mg, which is a novel formulation of aspirin that uses the PLxGuard delivery system to reduce acute gastrointestinal side effects while providing antiplatelet effectiveness for cardiovascular disease prevention. The company also offers publications and research services. PLx Pharma is headquartered in Sparta, New Jersey, the US.

For a complete picture of Ibuprofen’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.